Cannabidiphorol (CBDP) acts as a negative allosteric modulator at two distinct sites of cannabinoid receptor 1
Pankaj Pandey·Amar G. Chittiboyina·Shamba Chatterjee·Jason J. Paris·A H Zagzoog·Theodor Zaharia·Ikhlas A. Khan·Robert B. Laprairie
While Δ<sup>9</sup>-tetrahydrocannabinol (THC) offers significant pain relief, its psychoactive side effects limit its clinical utility. The discovery of cannabidiol (CBD) as a negative allosteric modulator (NAM) of cannabinoid receptor 1 (CB1R) establishes allosteric targeting as a viable framework for refining cannabinoid-based therapeutics. Cannabidiphorol (CBDP), a naturally occurring homolog of CBD identified from the FM2 chemovar of Cannabis sativa, is structurally similar to CBD but its p